WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328099
CAS#: 211735-76-1
Description: Farampator, also known as Org-24448; CX-691, is an AMPA receptor positive allosteric modulator potentially for the treatment of schizophrenia.
Hodoodo Cat#: H328099
Name: Farampator
CAS#: 211735-76-1
Chemical Formula: C12H13N3O2
Exact Mass: 231.10
Molecular Weight: 231.255
Elemental Analysis: C, 62.33; H, 5.67; N, 18.17; O, 13.84
Synonym: Farampator; Org-24448; CX-691; Org24448; CX691.
IUPAC/Chemical Name: 1-(2,1,3-Benzoxadiazol-5-ylcarbonyl)piperidine
InChi Key: XFVRBYKKGGDPAJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C12H13N3O2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8H,1-3,6-7H2
SMILES Code: O=C(N1CCCCC1)C2=CC3=NON=C3C=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 231.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Jardemark K, Marcus MM, Malmerfelt A, Shahid M, Svensson TH. Differential
effects of AMPA receptor potentiators and glycine reuptake inhibitors on
antipsychotic efficacy and prefrontal glutamatergic transmission.
Psychopharmacology (Berl). 2012 May;221(1):115-31. doi:
10.1007/s00213-011-2554-3. PubMed PMID: 22068461.
2: Woolley ML, Waters KA, Gartlon JE, Lacroix LP, Jennings C, Shaughnessy F, Ong
A, Pemberton DJ, Harries MH, Southam E, Jones DN, Dawson LA. Evaluation of the
pro-cognitive effects of the AMPA receptor positive modulator,
5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.
Psychopharmacology (Berl). 2009 Jan;202(1-3):343-54. doi:
10.1007/s00213-008-1325-2. PubMed PMID: 18795266.
3: Dawson N, Ferrington L, Olverman HJ, Kelly PA. Novel analysis for improved
validity in semi-quantitative 2-deoxyglucose autoradiographic imaging. J Neurosci
Methods. 2008 Oct 30;175(1):25-35. doi: 10.1016/j.jneumeth.2008.07.020. PubMed
PMID: 18762213.
4: Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the
ampakine farampator on memory and information processing in healthy elderly
volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. PubMed PMID:
17119538.
5: Jordan GR, McCulloch J, Shahid M, Hill DR, Henry B, Horsburgh K. Regionally
selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on
local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose
autoradiography. Neuropharmacology. 2005 Aug;49(2):254-64. PubMed PMID: 15993447.